The publication of this infographic was funded by Almirall.
This infographic highlights how Lebrikizumab, a selective IL-13 inhibitor, provides short- and long-term disease control in moderate-to-severe atopic dermatitis (AD). It covers AD pathophysiology, epidermal barrier dysfunction, IL-13’s role in AD, and Lebrikizumab’s mechanisms of action. The ADvocate 1 and ADvocate 2 monotherapy trials’ design is also detailed.
